Michael Niessen
Bonn, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Olfactory function as an independent prognostic factor in glioblastoma.
Journal: Neurology
Published: March 15, 2019
Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.
Journal: Journal of cancer research and clinical oncology
Published: April 11, 2018
Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.
Journal: Neuro-oncology
Published: November 10, 2017
The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma.
Journal: Journal of cancer research and clinical oncology
Published: May 09, 2016
Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.
Journal: Journal of cancer research and clinical oncology
Published: March 02, 2016
Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 09, 2015
18F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report.
Journal: Oncology letters
Published: December 09, 2014
Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma.
Journal: Oncology
Published: December 28, 2013
Dietary nitrate supplementation improves revascularization in chronic ischemia.
Journal: Circulation
Published: September 21, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026